CA2468700A1 - Extended glucagon-like peptide-1 analogs - Google Patents

Extended glucagon-like peptide-1 analogs Download PDF

Info

Publication number
CA2468700A1
CA2468700A1 CA002468700A CA2468700A CA2468700A1 CA 2468700 A1 CA2468700 A1 CA 2468700A1 CA 002468700 A CA002468700 A CA 002468700A CA 2468700 A CA2468700 A CA 2468700A CA 2468700 A1 CA2468700 A1 CA 2468700A1
Authority
CA
Canada
Prior art keywords
ser
gly
glp
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468700A
Other languages
English (en)
French (fr)
Inventor
Wolfgang Glaesner
Wayne David Kohn
Rohn Lee Junior Millican
Lianshan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468700A1 publication Critical patent/CA2468700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002468700A 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs Abandoned CA2468700A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34647402P 2002-01-08 2002-01-08
US60/346,474 2002-01-08
US40509702P 2002-08-21 2002-08-21
US60/405,097 2002-08-21
PCT/US2003/000001 WO2003058203A2 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Publications (1)

Publication Number Publication Date
CA2468700A1 true CA2468700A1 (en) 2003-07-17

Family

ID=26994870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468700A Abandoned CA2468700A1 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Country Status (11)

Country Link
US (1) US7482321B2 (cg-RX-API-DMAC7.html)
EP (1) EP1585959A4 (cg-RX-API-DMAC7.html)
JP (1) JP4282485B2 (cg-RX-API-DMAC7.html)
AR (1) AR038102A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003200839B2 (cg-RX-API-DMAC7.html)
BR (1) BR0306706A (cg-RX-API-DMAC7.html)
CA (1) CA2468700A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04006679A (cg-RX-API-DMAC7.html)
PE (1) PE20030820A1 (cg-RX-API-DMAC7.html)
TW (1) TW200306202A (cg-RX-API-DMAC7.html)
WO (1) WO2003058203A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066207A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
WO2006023358A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1845105A4 (en) 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical MODIFIED EXENDINES AND CORRESPONDING USES
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2606894A1 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
CN101166545B (zh) * 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物
WO2007021498A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
AU2006306236B2 (en) 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
US20100048460A1 (en) * 2006-02-28 2010-02-25 Lianshan Zhang Selective vpac2 receptor peptide agonists
WO2007113205A1 (en) * 2006-04-03 2007-10-11 Novo Nordisk A/S Glp-1 peptide agonists
CA2648936C (en) 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
KR20110039230A (ko) * 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
IN2012DN06437A (cg-RX-API-DMAC7.html) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
TWI538687B (zh) 2010-11-24 2016-06-21 杜瑞克公司 生物可降解之藥物遞送組成物
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
EP2729157B1 (en) * 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
WO2013078396A2 (en) 2011-11-23 2013-05-30 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
ES2646538T3 (es) * 2013-06-20 2017-12-14 Novo Nordisk A/S Derivados de GLP-1 y sus usos
CA2932477C (en) 2013-12-06 2023-10-10 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
HUE067499T2 (hu) 2018-04-05 2024-10-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737479T4 (de) * 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
DK1355942T3 (da) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
EP2022505B1 (en) * 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066207A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action

Also Published As

Publication number Publication date
WO2003058203A2 (en) 2003-07-17
PE20030820A1 (es) 2003-10-04
AU2003200839B2 (en) 2008-12-11
EP1585959A2 (en) 2005-10-19
WO2003058203A3 (en) 2007-02-01
BR0306706A (pt) 2007-03-27
JP2005528337A (ja) 2005-09-22
US20060014241A1 (en) 2006-01-19
TW200306202A (en) 2003-11-16
JP4282485B2 (ja) 2009-06-24
EP1585959A4 (en) 2007-11-14
MXPA04006679A (es) 2004-11-10
AU2003200839A1 (en) 2003-07-24
US7482321B2 (en) 2009-01-27
AR038102A1 (es) 2004-12-29

Similar Documents

Publication Publication Date Title
US7482321B2 (en) Extended glucagon-like peptide-1 analogs
AU2003200839A2 (en) Extended glucagon-like peptide-1 analogs
KR100593348B1 (ko) 글루카곤-유사 펩티드-1 유사체
CA2412004C (en) Glucagon-like peptide-1 analogs
KR20150116465A (ko) 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
KR20190119676A (ko) 글루카곤 및 glp-1 공-효능제 화합물
AU2001264791A1 (en) Glucagon-like peptide-1 analogs
CN101273058A (zh) 增强肽酶抗性的glp-1（胰高血糖素样肽-1）融合多肽
CA2468100A1 (en) Insulin molecule having protracted time action
US7566691B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
KR100997835B1 (ko) 엑센딘 4 폴리펩타이드 단편
US20060252693A1 (en) Glucagon-like peptide-1 analogs
HK1055121B (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead